What's in WYETH AYERST's pipeline?

WYETH AYERST has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with WYETH AYERST's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/wyeth-ayerst.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

WYETH AYERST — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WYETH AYERST pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
GRISACTIN ULTRA	GRISEOFULVIN, ULTRAMICROCRYSTALLINE	marketed		Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin	Dermatology
PREMPRO/PREMPHASE	CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE	marketed			Other

Therapeutic area mix

Dermatology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for WYETH AYERST:

Cite this brief

Drug Landscape (2026). WYETH AYERST — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wyeth-ayerst. Accessed 2026-06-10.